食管胃结合部腺癌患者经胸与经腹食管裂孔手术的疗效比较

目的 探讨对食管胃结合部腺癌患者采用不同的手术方式的治疗效果.方法 选取326例食管胃结合部腺癌患者,采用不同的手术入路,分为经胸、经腹、经胸腹联合组,观察比较三组患者术中出血量、手术时间、食管切除长度、淋巴结清扫数目、成功率等;术后记录患者住院天数、住院费用、抗生素应用时间、术后疼痛评分等;术后并发症发生情况.结果 与经胸、经腹入路组比较,经胸腹联合组术中出血量多;手术时间延长;食管切除长度缩短;淋巴结清扫数目增多;手术成功率高,组间比较差异均有统计学意义(P＜0.05);住院天数缩短;住院费用少;抗生素使用时间缩短;术后疼痛评分降低,差异均有统计学意义(P＜0.05);术后肺部感染9.09％,腹腔感染4.55％,无术后出血、吻合口狭窄、吻合口瘘者,均明显低于经胸、经腹组,差异均有统计学意义(P＜0.05).结论 对食管胃结合部腺癌患者采取经胸腹联合入路,手术时间短,术中出血量少,食管切除少,淋巴结清扫彻底,手术成功率高,并且可减轻术后疼痛,降低感染发生,缩短住院时间,减少住院费用,降低术后并发症的发生,优化治疗效果,值得广泛推广.     

贲门癌手术入路的前瞻性临床研究

 目的　探讨经左胸行贲门癌切除术达到肿瘤完全切除的可行性,比较经左胸和经腹两种手术入路的根治性切除率。方法　共有19例贲门癌患者入组。首先经左胸第7肋间后外侧切口进胸行贲门癌切除,食管-胃弓下吻合,关胸后经上腹部切口入路行规范区域淋巴结清扫（D2术式）。两次手术切除标本分别送病理科检查。结果　该组无手术死亡,无围手术期严重并发症发生。开腹手术中,19例标本共发现淋巴结122枚,7例（37 %）患者开腹手术标本中存在转移淋巴结（23枚）,按国际抗癌联盟（UICC）第6版胃癌TNM分期系统,6例分期得以调整。结论　对于进展期贲门癌,单纯经左胸手术不能完全切除原发肿瘤及转移淋巴结,尤其是腹腔转移淋巴结。     

食管胃交界部腺癌SiewertⅠ型和Ⅱ型胸外科手术治疗效果及预后研究

背景与目的：随着食管癌和胃癌发病率降低,食管胃交界部腺癌（adenocarcinoma of the esophagogastric junction,AEG）发病率近些年呈现缓慢上升的趋势。探讨SiewertⅠ型、Ⅱ型AEG外科治疗方法、淋巴结清扫规律及预后。方法：选取2012年1月—2014年1月在河北医科大学第四医院胸外科同一手术治疗组经手术治疗且术前经电子胃镜检查和术后病理学检查均证实为SiewertⅠ型和Ⅱ型AEG患者共计240例,分为SiewertⅠ型和Ⅱ型两组,生存率的计算采用寿命表法,单因素生存分析采用Kaplan-Meier法分析,组间生存率差异采用log-rank检验,预后因素的多因素生存分析采用Cox回归模型。根据手术方式分为经胸入路组和经胸腹入路组,对两种手术方式采用Kaplan-Meier法进行单因素分析。结果：经胸入路组在手术时间上少于经胸腹入路组,在术后呼吸系统并发症发生率上高于经胸腹入路组;SiewertⅠ型3、5年总生存率分别为36.4%、25.0%;TNM分期、淋巴结分期、淋巴结清扫个数和新辅助化疗患者预后比较,差异有统计学意义（P<0.05）。SiewertⅡ型3、5年总生存率分别为41.7%、29.9%;不同TNM分期、淋巴结分期、手术入路和新辅助化疗患者预后比较,差异有统计学意义（P<0.05）。Cox比例风险回归模型分析结果显示,TNM分期（HR=3.877,95% CI：0.765~1.979,P=0.019）、淋巴结分期（HR=21.753,95% CI：0.745~1.971,P=0.007）、淋巴结清扫数量（HR=4.113,95% CI：1.511~4.832,P=0.025）和新辅助化疗（HR=6.711,95% CI：1.511~3.977,P=0.041）是影响SiewertⅠ型AEG患者预后的独立因素;TNM分期（HR=6.387,95% CI：0.775~1.932,P=0.031）、淋巴结分期（HR=2.343,95% CI：0.730~2.112,P=0.038）、手术入路（HR=2.991,95% CI：1.592~5.871,P=0.035）、淋巴结清扫数量（HR=3.179,95%CI：1.511~4.832,P=0.032）和新辅助化疗（HR=3.459,95% CI：1.732~4.977,P=0.025）是影响Siewert Ⅱ型AEG患者预后的独立因素。结论：SiewertⅠ型和SiewertⅡ型AEG的治疗应由胸外科完成,病理学分期参考国际抗癌联盟（Union for International Cancer Control,UICC）第8版食管癌分期。经胸入路适合SiewertⅠ型、局限期的患者,经胸腹入路适合SiewertⅡ型、进展期的患者。SiewertⅠ型和SiewertⅡ型AEG手术上切缘的切除范围的安全性和淋巴结转移程度是制约AEG预后的重要因素。对进展期的患者应尽可能地选择术前新辅助化疗。     

胃底贲门癌手术治疗方式的探讨

目的 探讨提高胃底贲门癌手术切除率及远期疗效的最佳方法；探讨手术路径、操作要点及并发症的预防措施。方法 对比分析单纯经胸或单纯经腹的近端胃切除与经胸、腹联舍切口行全胃切除术对疾病远期效果的影响。结果 胸外科经胸近端胃切除36例；普外科单纯经腹近端胃切除10例，全胃切除3例；经胸腹联合切口全胃切除79例。比较：近端胃切除不利于淋巴结清扫，达不到根治效果。经胸腹联合切口的全胃切除既有利于淋巴结清扫，又能切除足够长度的食管，手术切除率高。结论 胃底贲门癌经胸腹联合切口全胃切除效果好。     

贲门癌手术入路的前瞻性临床研究

目的 探讨经左胸行贲门癌切除术达到肿瘤完全切除的可行性,比较经左胸和经腹两种手术入路的根治性切除率.方法 共有19例贲门癌患者入组.首先经左胸第7肋间后外侧切口进胸行贲门癌切除,食管-胃弓下吻合,关胸后经上腹部切口入路行规范区域淋巴结清扫(D2术式).两次手术切除标本分别送病理科检查.结果 该组无手术死亡,无围手术期严重并发症发生.开腹手术中,19例标本共发现淋巴结122枚,7例(37%)患者开腹手术标本中存在转移淋巴结(23枚),按国际抗癌联盟(UICC)第6版胃癌TNM分期系统,6例分期得以调整.结论 对于进展期贲门癌,单纯经左胸手术不能完全切除原发肿瘤及转移淋巴结,尤其是腹腔转移淋巴结.     

贲门癌手术入路的前瞻性临床研究

目的 探讨经左胸行贲门癌切除术达到肿瘤完全切除的可行性,比较经左胸和经腹两种手术入路的根治性切除率.方法 共有19例贲门癌患者入组.首先经左胸第7肋间后外侧切口进胸行贲门癌切除,食管-胃弓下吻合,关胸后经上腹部切口入路行规范区域淋巴结清扫(D2术式).两次手术切除标本分别送病理科检查.结果 该组无手术死亡,无围手术期严重并发症发生.开腹手术中,19例标本共发现淋巴结122枚,7例(37%)患者开腹手术标本中存在转移淋巴结(23枚),按国际抗癌联盟(UICC)第6版胃癌TNM分期系统,6例分期得以调整.结论 对于进展期贲门癌,单纯经左胸手术不能完全切除原发肿瘤及转移淋巴结,尤其是腹腔转移淋巴结.     

不同手术入路对Ⅱ、Ⅲ型食管胃结合部腺癌患者术后生活质量及生存的影响

目的 前瞻性分析Ⅱ、Ⅲ型食管胃结合部腺癌（AEG）经胸入路与经腹食管裂孔切开入路根治术对患者近期生活质量及总生存期等的影响,探讨Ⅱ、Ⅲ型AEG手术入路的合理选择.方法 2012年3月至2012年9月间山西省肿瘤医院前瞻性研究入组Ⅱ、Ⅲ型AEG患者139例,其中经胸入路组（经胸组）64例,经腹食管裂孔切开入路组（经腹组）75例,分别对两组的手术时间、切缘癌残留阳性率、平均清扫淋巴结数目、术后平均住院天数、胃肠功能恢复所需平均天数、围手术期心肺并发症发生率、吻合口瘘发生率、术后出血发生率、围手术期死亡率、术后1年内呼吸功能下降率、术后1年内体质量下降平均值、术后1年内反流率、术后1年复发转移率、1年生存率等指标进行统计对比分析.结果 139例患者中,26例失访,失访率为18.7％,随访病例113例.经胸组和经腹组患者的术后平均住院时间分别是（20.2±8.9）d、（17.1±6.4）d,两组间差异有统计学意义（P＜0.05）;两组平均清扫淋巴结数目分别为（15.2±7.5）个、（23.0±13.0）个,两组间差异有统计学意义（P＜0.05）.两组病例的手术时间、切缘癌残留阳性率、胃肠功能恢复平均天数、围手术期心肺并发症发生率、吻合口瘘发生率、术后出血发生率、围手术期死亡率、术后1年内呼吸功能下降率、术后1年内体质量下降平均值、术后1年内反流发生率、术后1年复发转移率及术后1年生存率差异均无统计学意义（均P＞0.05）.结论 Ⅱ、Ⅲ型AEG手术入路以经腹经食管裂孔切开根治术式为优先选择.经腹入路清扫淋巴结数目较经胸入路多,对预后可能有一定影响.     

经腹食管裂孔径路行食管胃交界部腺癌根治术264例

 目的　探讨经腹食管裂孔径路进行食管胃交界部腺癌（AEG）根治性手术的合理性、优越性。方法　对264例AEG患者经腹食管裂孔径路行根治性切除的资料进行回顾性分析。结果　264例AEG经腹食管裂孔径路完成根治术。其中,AEG Ⅰ型2例,Ⅱ型、Ⅲ型共262例。行全胃切除103例,近端胃切除161例,联合脾切除3例,联合胆囊切除或（和）胆总管探查取结石20例。根治性近端胃切除清扫淋巴结8～30枚,平均19.1枚;根治性全胃切除清扫淋巴结8～36枚,平均22枚。无围手术期心、肺功能障碍死亡,术后并发症减少。结论　经腹食管裂孔径路不但能满足AEG根治术中对 腹部脏器切除、淋巴清扫的需要,也能满足对第110、111组淋巴结清扫及食管下段切除的要求,减少了开胸手术的创伤,对AEG进行根治手术可以选择经腹食管裂孔径路。     

经胸与经腹食管裂孔手术治疗高龄食管胃结合部腺癌患者的近期效果比较

目的比较经胸与经腹食管裂孔手术治疗高龄食管胃结合部腺癌患者的近期效果。方法回顾性分析2013年8月至2016年2月江南大学附属医院行食管胃结合部癌切除术92例高龄患者临床资料,其中经左胸入路（经胸组）47例,经腹正中入路（经腹组）45例。比较两组患者的一般资料及手术时间、术中出血量、淋巴结清扫数目、术后住院时间及术后并发症的发生率。结果两组患者的手术时间、术中出血量和淋巴结清扫数目无统计学差异（均P≥0．05）。与经胸组相比,经腹组患者获取阳性淋巴结数目更多[（8．1±5．0）枚 vs．（5．1±4．4）枚,t＝3．000,P＝0．003],术后住院时间更短[（11．7±6．9）天vs．（15．9±7．4）天,t＝2．773,P＝0．007）],术后并发症发生率较低（13．3％ vs．44．7％,χ2＝10．895,P＝0．001）,其中肺部感染（2．2％ vs．14．9％,χ2＝4．649,P＝0．031）、心律失常（4．4％ vs 19．1％,χ2＝4．722,P＝0．030）发生率均较低。两组患者的吻合口瘘、切口感染、纵膈或胸腔感染的发生率均无统计学差异（均P≥0．05）。两组患者均无切缘阳性和围术期死亡病例。结论对于心肺功能差的高龄食管胃结合部腺癌患者,经腹食管裂孔入路比经胸入路手术在对心肺功能影响较小,能够显著降低术后并发症的发生率,缩短住院时间。     

经左、右胸两种不同的手术入路对食管中下段癌疗效的影响

目的探讨经左、右胸2种不同手术入路治疗食管中下段癌的临床效果。方法选择食管中下段癌患者60例。在治疗过程中,按分配床位单、双数,将患者分为2组,采取不同的入路方式,即左胸后外侧入路组(左胸组);右胸前外侧、腹正中入路组(右胸组)。结果右胸组手术时间、术中出血量较左胸组显著增加(P<0.001)。右胸组围手术期并发症发生率为44.9%,左胸组为23.1%(P<0.001)。其中,右胸组肺部并发症发生率较左胸组明显增多(14.1%VS 7.1%,P<0.001)。左胸组平均清扫淋巴结(12±5)枚,右胸组(18±10)枚(P<0.001)。从送检淋巴结的解剖分布情况来看,右胸组平均清扫上纵隔淋巴结(包括右喉返神经旁、胸内气管旁组淋巴结)数目明显比左胸组增多。右胸组局部复发率及远处转移率均低于左胸组(P<0.05)。结论对于食管中下段癌,选择右胸手术入路更为合理。     

食管胃交界部癌外科治疗中淋巴结清扫的范围和价值

Objective  

We studied the extent and value of the lymphadenectomy in surgical treatment of carcinoma of gastroesophageal junction (GEJ).     

Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.

BACKGROUND: Paclitaxel (T), etoposide (E), and cisplatin (P) are each active in gastric carcinoma, either as single agents or as part of a multidrug regimen. To the authors' knowledge, the combination of these three agents in the treatment of patients with esophageal or gastroesophageal carcinoma has not been previously studied. METHODS: Previously untreated patients with locally advanced carcinoma of the stomach, esophagus, or gastroesophageal (GE) junction received at least 2 cycles of TPE administered twice weekly for 3 weeks, with the cycle repeated every 28 days. Drug doses, administered over 3 hours on either Monday and Thursday or Tuesday and Friday, consisted of T 50 mg/m2/dose, P 15 mg/m2/dose, and E 40 mg/m2/dose. For patients with local disease only, subsequent therapy consisted of radiation with or without surgical resection. RESULTS: Twenty-five patients with gastric (10) or gastroesophageal or GE junction (15) carcinoma were treated. Eighteen had locally advanced disease and 7 had liver metastases at presentation. Hematologic toxicity, namely, Grade 3 anemia and neutropenia, was experienced by all patients. The median number of treatment cycles was 4 (range, 2-6). Three patients were not evaluable for response. All 22 evaluable patients responded; 3 were complete responders and 19 were partial responders. Eleven patients received radiation therapy with (6) or without (5) concomitant 5-fluorouracil, and 8 patients subsequently underwent surgical resection. Three of 8 patients had no tumor at surgery, 4 had minimal microscopic tumor at the primary site, and 3 had microscopic lymph node involvement. Twenty-three patients are alive, of whom 14 are without evidence of disease. Two patients with metastatic disease at presentation died at 9 and 29 months, respectively. The median survival was 12.5 months (range, 6 to 30+ months). CONCLUSIONS: Multifractionated TPE chemotherapy is a highly active regimen in gastric and gastroesophageal carcinoma. It could be evaluated in Phase III trials against other active regimens for the treatment of patients with this disease. The introduction of 5-fluorouracil could also be an interesting direction to explore because of its primary role in the treatment of patients with gastric and esophageal carcinoma.     

胃食管结合部癌Her－2基因扩增及蛋白表达与临床病理关系

目的：通过检测表皮生长因子－2（ Her－2）在胃食管结合部癌中的蛋白表达和基因扩增情况,探讨其与胃食管结合部癌患者的临床病理关系。方法采用免疫组织化学法（ IHC）和荧光原位杂交技术（ FISH）检测80例手术切除的胃食管结合部癌组织中Her－2的蛋白表达和基因扩增情况,并分析与胃食管结合部癌的病理分化程度、浸润深度、临床分期和淋巴结转移的关系。结果应用FISH技术检测显示在胃食管结合部癌组织中Her－2的蛋白阳性表达率为22．5％,应用IHC技术检测其在癌组织表达率为15％,Her－2基因扩增和蛋白阳性表达与胃食管结合部癌的分化程度和临床TNM分期有关（ P＜0．05）,而与年龄、性别和浸润深度及淋巴结转移无相关性。结论 Her－2蛋白过表达和基因扩增是胃食管结合部癌患者的一个预后指标,与其发生发展有关,联合检测Her－2蛋白表达水平及基因扩增程度对于胃食管结合部癌的治疗和预后评估有一定指导意义。     

SATB1在SiewertⅡ、Ⅲ型胃食管结合部腺癌中的表达及与临床病理特征的关系

目的:研究特异性核基质结合区蛋白质-1(SATB1)在SiewertⅡ、Ⅲ型胃食管结合部腺癌组织中的表达及与临床病理特征的关系.方法:经免疫组化染色(SP法)检测80例SiewertⅡ、Ⅲ型胃食管结合部组织中SATB1蛋白表达.结果:SiewertⅡ、Ⅲ型胃食管结合部腺癌组织中SATB1的阳性表达共30例,阳性表达率为37.5%;而正常胃黏膜组织中SATB1阳性表达18例,阳性表达率为22.5%,差异具有统计学意义(x2=4.286,P<0.05).淋巴结转移(x2=5.150,P<0.05)及肿瘤浸润深度(x2=4.364,P<0.05)是胃食管结合部腺癌的独立影响因素.结论:SATB1蛋白在SiewertⅡ、Ⅲ型胃食管结合部腺癌中表达强于正常黏膜组织.SATB1蛋白阳性表达与肿瘤浸润程度、淋巴结转移成正相关性,可作为评估SiewertⅡ、Ⅲ型胃食管结合部腺癌肿瘤进展的一种指标.     

Esophageal cancer

The important concepts of carcinoma of the esophagus are reviewed in this article. Pathology of malignant esophageal tumors is described and tumor behavior of squamous cell carcinoma is discussed and illustrated. Various classifications and staging methods are reviewed with emphasis placed on the TNM system. The role of current imaging techniques in patients with esophageal carcinoma is presented. Computed tomography is discussed and illustrated in detail. The relative cost effectiveness of these procedures is presented and an imaging approach emphasizing TNM staging is described for patients with known carcinoma of the esophagus. This imaging approach is integrated with the basic aspects of treatment and both curative and palliative pathways are presented. The final section of the article deals with these same concepts in patients with carcinoma of the gastroesophageal junction. The important differences between adenocarcinoma of the gastroesophageal junction and esophageal carcinoma are described.     

Systematic review of the surgical strategies of adenocarcinomas of the gastroesophageal junction

IntroductionThe optimal surgical treatment of patients with adenocarcinoma of the gastroesophageal junction has not been established yet.ObjectiveTo evaluate the surgical strategies to treat adenocarcinoma of the gastroesophageal junction.MethodsDatabases Pubmed, Cochrane, and Embase were searched for “adenocarcinoma of the gastroesophageal junction” AND (“surgery” OR “esophagectomy” OR “gastrectomy”) or its synonyms or abbreviations. Only comparative studies that evaluated gastrectomy versus esophagectomy were included.ResultsIn total 10 cohort studies comparing esophagectomy versus gastrectomy fulfilled the quality criteria. The R0 resection rates varied between 72–93% for esophagectomy and 62%–93% for gastrectomy. Morbidity was 33–39% after esophagectomy versus 11–54% after gastrectomy. The 30-day mortality ranged between 1.0–2.3 after esophagectomy and 1.8–2.7% after gastrectomy. At 6 months after surgery, health-related quality of life was higher after total gastrectomy than after esophagectomy. The 5-year survival rates varied between 30–42% for esophagectomy and 18–38% for gastrectomy, but were not significantly different.ConclusionNo clear oncologic benefit of either esophagectomy or gastrectomy in patients with adenomacarcinoma of gastroesophageal junction could be observed. However, gastrectomy seems to be accompanied with better quality of life. Future research should preferably consist of a multicenter RCT comparing esophagectomy and gastrectomy for adenocarcinomas of the gastroesophageal junction.     

Cancer of the esophagogastric junction

In the Western world, there has been an alarming rise in the incidence and prevalence of adenocarcinoma arising at the esophagogastric junction during recent decades. Epidemiological, clinical and pathological data support a sub-classification of adenocarcinomas arising in the vicinity of the esophagogastric junction (AEG) into adenocarcinoma of the distal esophagus (Type I), true carcinoma of the cardia (Type II) and subcardial carcinoma (Type III). While most, if not all, adenocarcinomas of the distal esophagus arise from areas with specialized intestinal metaplasia, which develop as a consequence of chronic gastroesophageal reflux, the etiology and pathogenesis of true carcinoma of the gastric cardia and subcardial gastric cancer is not clear at present. Although a subgroup of true carcinomas of the gastric cardia may also develop within short segments of intestinal metaplasia at the esophagogastric junction, a causal relation between these tumors and gastroesophageal reflux has been difficult to establish. Irrespective of the etiology, a complete removal of the primary tumor and its lymphatic drainage has to be the primary goal of any surgical approach to adenocarcinoma of the esophagogastric junction. Our experience in the management of more than 1000 such patients during the past 18 years suggests that an individualized therapeutic strategy oriented by tumor type and stage results in survival rates superior to those reported with a more indiscriminate approach. This individualized strategy prescribes a transmediastinal esophagectomy with lymphadenectomy in the lower posterior mediastinum and along the celiac axis for Type I tumors, extended total gastrectomy with transhiatal resection of the distal esophagus and D2 lymphadenectomy for Type II and Type III tumors, a limited resection of the esophagogastric junction and distal esophagus with interposition of a pedicled jejunal segment for uT1N0 tumors, and neoadjuvant chemotherapy followed by resection for uT3/T4 tumors. Extensive preoperative staging is essential to allow correct selection of the appropriate therapeutic strategy using this tailored approach.     

Systemic chemotherapy does not increase the risk of gastrointestinal perforation.

BACKGROUND: Gastrointestinal perforation is a rare complication of gastric cancer. Although there is the perception of chemotherapy aggravating the perforation risk, the rate of perforation in patients with gastric cancer receiving chemotherapy is unknown. This study describes the incidence and clinical course of patients with gastric or gastroesophageal junction (GEJ) carcinoma who experience a perforation while receiving chemotherapy. PATIENTS AND METHODS: The records of patients with gastric or GEJ adenocarcinoma over a 6-year period who received chemotherapy for locally advanced or metastatic disease were reviewed. Extracted information included demographics, treatment received, and overall survival was calculated. RESULTS: 1032 patients at MSKCC received systemic cytotoxic chemotherapy for locally advanced or metastatic gastric or GEJ carcinoma; 11 patients experienced a perforation (1.1%, 95% CI 0.5-1.9%); 5/11 (45%) patients received further chemotherapy and had a median survival of 5.6 months. CONCLUSIONS: The rate of perforation in patients with advanced GEJ/gastric adenocarcinoma receiving chemotherapy is 1.1%, which is the same rate as in surgical series of patients presenting with perforation. Chemotherapy does not significantly add to the risk of gastrointestinal perforation.     

A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction

BACKGROUND: Patients with locoregional carcinoma of the esophagus or gastroesophageal junction have a poor survival rate after surgery. Preoperative chemotherapy or chemoradiotherapy has not improved the outcome for these patients. Our study was designed to assess the feasibility of preoperative induction combination chemotherapy in addition to chemoradiotherapy to improve the curative resection rate, local control, and survival. PATIENTS AND METHODS Patients having histologic proof of localized carcinoma (either squamous cell carcinoma or adenocarcinoma) of the esophagus or gastroesophageal junction underwent full classification including endoscopic ultrasonography (EUS). Patients first received up to two courses of induction chemotherapy consisting of 5-fluorouracil at 750 mg/m(2)/day as continuous infusion on Days 1--5, cisplatin at 15 mg/m(2)/day as an intravenous bolus on Days 1--5, and paclitaxel at 200 mg/m(2) as a 24-hour intravenous infusion on Day 1. The second course was repeated on Day 29. This was followed by radiotherapy (45 grays in 25 fractions) and concurrent admission of 5-fluorouracil (300 mg/m(2)/day as a continuous infusion 5 days/week) and cisplatin (20 mg/m(2) on Days 1--5 of radiotherapy). After chemoradiotherapy, patients underwent surgery. The feasibility of this approach, curative resection rates, patient survival, and patterns of failure were assessed. RESULTS: Thirty-seven of 38 patients enrolled were evaluable for toxicity and survival. Adenocarcinoma and distal esophageal location of carcinoma were observed frequently. Thirty-five (95%) of the 37 patients underwent surgery, all of whom had an R0 (curative) resection. A pathologic complete response was noted in 11 (30%) of the 37 total patients. In addition, 5 patients (14%) had only microscopic carcinoma. According to EUS classification, 31 (89%) of the 35 patients who underwent surgery had a T3 carcinoma whereas according to pathologic classification only 3 (9%) had a T3 carcinoma (P 相似文献   

外科治疗43例高龄食管癌贲门癌

目的：探讨高龄食管癌贲门癌病人围手术期的处理和手术方式的选择。方法：43例肿瘤患者中,食管癌26例,根治手术23例,探查3例,贲门癌17例,根治手术13例,探查4例,对食管癌贲门癌的术前准备、营养支持及手术方式进行总结分析。结果：本组手术切除率93．0％、并发症发生率41．9％、手术死亡率4．7％,获得了较满意的治疗结果。结论：对高龄食管癌和贲门癌病人,应严格掌握适应证及正确处理围手术期并发症。